Cargando…

Duodenal Microbiome and Serum Metabolites Predict Hepatocellular Carcinoma in a Multicenter Cohort of Patients with Cirrhosis

BACKGROUND: Hepatocellular carcinoma (HCC) is rapidly increasing in the U.S. and is a leading cause of mortality for patients with cirrhosis. Discovering novel biomarkers for risk stratification of HCC is paramount. We examined biomarkers of the gut-liver axis in a prospective multicenter cohort. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Tien S., Jacobs, Jonathan P., Agopian, Vatche, Pisegna, Joseph R., Ayoub, Walid, Durazo, Francisco, Enayati, Pedram, Sundaram, Vinay, Benhammou, Jihane N., Noureddin, Mazen, Choi, Gina, Lagishetty, Venu, Fiehn, Oliver, Goodman, Marc T., Elashoff, David, Hussain, Shehnaz K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287237/
https://www.ncbi.nlm.nih.gov/pubmed/34799768
http://dx.doi.org/10.1007/s10620-021-07299-2
_version_ 1784748208210051072
author Dong, Tien S.
Jacobs, Jonathan P.
Agopian, Vatche
Pisegna, Joseph R.
Ayoub, Walid
Durazo, Francisco
Enayati, Pedram
Sundaram, Vinay
Benhammou, Jihane N.
Noureddin, Mazen
Choi, Gina
Lagishetty, Venu
Fiehn, Oliver
Goodman, Marc T.
Elashoff, David
Hussain, Shehnaz K.
author_facet Dong, Tien S.
Jacobs, Jonathan P.
Agopian, Vatche
Pisegna, Joseph R.
Ayoub, Walid
Durazo, Francisco
Enayati, Pedram
Sundaram, Vinay
Benhammou, Jihane N.
Noureddin, Mazen
Choi, Gina
Lagishetty, Venu
Fiehn, Oliver
Goodman, Marc T.
Elashoff, David
Hussain, Shehnaz K.
author_sort Dong, Tien S.
collection PubMed
description BACKGROUND: Hepatocellular carcinoma (HCC) is rapidly increasing in the U.S. and is a leading cause of mortality for patients with cirrhosis. Discovering novel biomarkers for risk stratification of HCC is paramount. We examined biomarkers of the gut-liver axis in a prospective multicenter cohort. METHODS: Patients with cirrhosis without a history of HCC were recruited between May 2015 and March 2020 and prospectively followed at 3 tertiary care hospitals in Los Angeles. Microbiome analysis was performed on duodenal biopsies and metabolomic analysis was performed on serum samples, collected at the time of enrollment. Optimal microbiome-based survival analysis and Cox proportional hazards regression analysis were used to determine microbiota and metabolite associations with HCC development, respectively. RESULTS: A total of 227 participants with liver cirrhosis contributed a total of 459.58 person-years of follow-up, with 14 incident HCC diagnoses. Male sex (HR = 7.06, 95% CI = 1.02–54.86) and baseline hepatic encephalopathy (HE, HR = 4.65, 95% CI = 1.60–13.52) were associated with developing HCC over follow-up. Adjusting for age, sex, baseline HE, and alkaline phosphatase, an increased risk of HCC were observed for participants with the highest versus lowest three quartiles for duodenal Alloprevotella (HR = 3.22, 95% CI = 1.06–9.73) and serum taurocholic acid (HR = 6.87, 95% CI = 2.32–20.27), methionine (HR = 9.97, 95% CI = 3.02–32.94), and methioninesulfoxide (HR = 5.60, 95% CI = 1.84–17.10). Being in the highest quartile for Alloprevotella or methionine had a sensitivity and specificity for developing HCC of 85.71% and 60.56%, respectively, with an odds ratio of 10.92 (95% CI = 2.23–53.48). CONCLUSION: Alloprevotella and methionine, methioninesulfoxide, and taurocholic acid predicted future HCC development in a high-risk population of participants with liver cirrhosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10620-021-07299-2.
format Online
Article
Text
id pubmed-9287237
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-92872372022-07-17 Duodenal Microbiome and Serum Metabolites Predict Hepatocellular Carcinoma in a Multicenter Cohort of Patients with Cirrhosis Dong, Tien S. Jacobs, Jonathan P. Agopian, Vatche Pisegna, Joseph R. Ayoub, Walid Durazo, Francisco Enayati, Pedram Sundaram, Vinay Benhammou, Jihane N. Noureddin, Mazen Choi, Gina Lagishetty, Venu Fiehn, Oliver Goodman, Marc T. Elashoff, David Hussain, Shehnaz K. Dig Dis Sci Original Article BACKGROUND: Hepatocellular carcinoma (HCC) is rapidly increasing in the U.S. and is a leading cause of mortality for patients with cirrhosis. Discovering novel biomarkers for risk stratification of HCC is paramount. We examined biomarkers of the gut-liver axis in a prospective multicenter cohort. METHODS: Patients with cirrhosis without a history of HCC were recruited between May 2015 and March 2020 and prospectively followed at 3 tertiary care hospitals in Los Angeles. Microbiome analysis was performed on duodenal biopsies and metabolomic analysis was performed on serum samples, collected at the time of enrollment. Optimal microbiome-based survival analysis and Cox proportional hazards regression analysis were used to determine microbiota and metabolite associations with HCC development, respectively. RESULTS: A total of 227 participants with liver cirrhosis contributed a total of 459.58 person-years of follow-up, with 14 incident HCC diagnoses. Male sex (HR = 7.06, 95% CI = 1.02–54.86) and baseline hepatic encephalopathy (HE, HR = 4.65, 95% CI = 1.60–13.52) were associated with developing HCC over follow-up. Adjusting for age, sex, baseline HE, and alkaline phosphatase, an increased risk of HCC were observed for participants with the highest versus lowest three quartiles for duodenal Alloprevotella (HR = 3.22, 95% CI = 1.06–9.73) and serum taurocholic acid (HR = 6.87, 95% CI = 2.32–20.27), methionine (HR = 9.97, 95% CI = 3.02–32.94), and methioninesulfoxide (HR = 5.60, 95% CI = 1.84–17.10). Being in the highest quartile for Alloprevotella or methionine had a sensitivity and specificity for developing HCC of 85.71% and 60.56%, respectively, with an odds ratio of 10.92 (95% CI = 2.23–53.48). CONCLUSION: Alloprevotella and methionine, methioninesulfoxide, and taurocholic acid predicted future HCC development in a high-risk population of participants with liver cirrhosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10620-021-07299-2. Springer US 2021-11-20 2022 /pmc/articles/PMC9287237/ /pubmed/34799768 http://dx.doi.org/10.1007/s10620-021-07299-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Article
Dong, Tien S.
Jacobs, Jonathan P.
Agopian, Vatche
Pisegna, Joseph R.
Ayoub, Walid
Durazo, Francisco
Enayati, Pedram
Sundaram, Vinay
Benhammou, Jihane N.
Noureddin, Mazen
Choi, Gina
Lagishetty, Venu
Fiehn, Oliver
Goodman, Marc T.
Elashoff, David
Hussain, Shehnaz K.
Duodenal Microbiome and Serum Metabolites Predict Hepatocellular Carcinoma in a Multicenter Cohort of Patients with Cirrhosis
title Duodenal Microbiome and Serum Metabolites Predict Hepatocellular Carcinoma in a Multicenter Cohort of Patients with Cirrhosis
title_full Duodenal Microbiome and Serum Metabolites Predict Hepatocellular Carcinoma in a Multicenter Cohort of Patients with Cirrhosis
title_fullStr Duodenal Microbiome and Serum Metabolites Predict Hepatocellular Carcinoma in a Multicenter Cohort of Patients with Cirrhosis
title_full_unstemmed Duodenal Microbiome and Serum Metabolites Predict Hepatocellular Carcinoma in a Multicenter Cohort of Patients with Cirrhosis
title_short Duodenal Microbiome and Serum Metabolites Predict Hepatocellular Carcinoma in a Multicenter Cohort of Patients with Cirrhosis
title_sort duodenal microbiome and serum metabolites predict hepatocellular carcinoma in a multicenter cohort of patients with cirrhosis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287237/
https://www.ncbi.nlm.nih.gov/pubmed/34799768
http://dx.doi.org/10.1007/s10620-021-07299-2
work_keys_str_mv AT dongtiens duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis
AT jacobsjonathanp duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis
AT agopianvatche duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis
AT pisegnajosephr duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis
AT ayoubwalid duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis
AT durazofrancisco duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis
AT enayatipedram duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis
AT sundaramvinay duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis
AT benhammoujihanen duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis
AT noureddinmazen duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis
AT choigina duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis
AT lagishettyvenu duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis
AT fiehnoliver duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis
AT goodmanmarct duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis
AT elashoffdavid duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis
AT hussainshehnazk duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis